Noteworthy Price Action: Could Qiagen NV Go Down After Touching 52-Week High?

Noteworthy Price Action: Could Qiagen NV Go Down After Touching 52 Week High?

The stock of Qiagen NV (NASDAQ:QGEN) hit a new 52-week high and has $47.26 target or 66.00% above today’s $28.47 share price. The 9 months bullish chart indicates low risk for the $6.78 billion company. The 1-year high was reported on Nov, 9 by Barchart.com. If the $47.26 price target is reached, the company will be worth $4.47 billion more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock. About 903,520 shares traded hands. Qiagen NV (NASDAQ:QGEN) has risen 21.53% since April 7, 2016 and is uptrending. It has outperformed by 16.75% the S&P500.

Qiagen NV (NASDAQ:QGEN) Ratings Coverage

Out of 10 analysts covering Qiagen (NASDAQ:QGEN), 4 rate it a “Buy”, 0 “Sell”, while 6 “Hold”. This means 40% are positive. Qiagen has been the topic of 14 analyst reports since August 3, 2015 according to StockzIntelligence Inc. Stifel Nicolaus initiated the shares of QGEN in a report on Thursday, November 12 with “Hold” rating. The firm earned “Neutral” rating on Thursday, November 3 by Bank of America. On Tuesday, September 15 the stock rating was initiated by Morgan Stanley with “Overweight”. The firm has “Neutral” rating by Mizuho given on Thursday, July 30. The company was maintained on Thursday, July 30 by Barclays Capital. The stock of Qiagen NV (NASDAQ:QGEN) has “Neutral” rating given on Tuesday, March 15 by Citigroup.

According to Zacks Investment Research, “Qiagen NV produces biomedical and genetic products, products for separating and purifying nucleic acids for gene-based drug screening, nucleic acid-based clinical diagnostics, genetic vaccination and gene therapy.”

More recent Qiagen NV (NASDAQ:QGEN) news were published by: Fool.com which released: “Qiagen NV Jumps After Beating Its Earnings Guidance” on November 03, 2016. Also Prnewswire.com published the news titled: “QIAGEN N.V. to Report Third Quarter and First Nine Months of 2016 Results” on October 11, 2016. Prnewswire.com‘s news article titled: “QIAGEN GeneReader NGS System to Relaunch in U.S. Market” with publication date: November 09, 2016 was also an interesting one.

QGEN Company Profile

QIAGEN N.V. (QIAGEN), incorporated on April 29, 1996, is a holding company. The Firm and its subsidiaries are engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Sample to Insight solutions are composed of sample and assay technologies, bioinformatics and automation systems. The Company’s solutions support over 500,000 clients across the world in generating insights into the molecular building blocks of life. The Company’s over two billion biological samples have been prepared or analyzed using QIAGEN sample technologies. The Company’s sample technologies are used in isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. The Company’s assay technologies make these biomolecules visible for analysis, such as identifying the DNA of a virus or a gene mutation in a tumor. The Company’s bioinformatics solutions interpret data to provide actionable insights. The Company’s automation platforms tie these together in molecular testing workflows – from Sample to Insight. The Company’s Sample to Insight molecular technologies are applicable across a range of applications and customer classes through over 500 core consumable products, as well as instruments that automate the use of these products for sample preparation, analysis and interpretation. The Company’s bioinformatics solutions connect laboratory workflows and process amounts of genomic data, enabling scientists or clinicians to decide on further action. The Firm offers solutions in molecular diagnostics, applied testing, pharma and academia.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment